Imperial College London

Dr Evangelos Triantafyllou

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Lecturer in Liver Immunology



e.triantafyllou Website




10.N12ACommonwealth BuildingHammersmith Campus






Evangelos Triantafyllou is Principal Investigator and Lecturer in Liver Immunology (Section of Hepatology & Gastroenterology). He holds a BSc in Biology (University of Athens, 2011) and a MSc in Developmental Biology (University of Bath, 2012). He undertook his PhD in Liver Immunology (King’s College London, Institute of Liver Studies, 2017) investigating the mechanisms of immune-mediated injury in liver failure, having spent a part of his doctoral work at the University of Birmingham (Centre for Liver & Gastrointestinal Research, 2014). In 2017 he joined Imperial College London for post-doctoral research on immune dys-regulation after acute and chronic liver injury, with a special focus on myeloid cell inflammatory and bactericidal functions. He has been awarded funding from the Rosetrees Trust (2017, 2021), an Imperial College Research Fellowship (2018) and a UKRI MRC New Investigator Research Grant (2023).

Triantafyllou Lab:

Our group is located on Hammersmith campus (Commonwealth Building, 10th floor) and includes a close collaboration between scientists and clinicians and conducts basic, translational, and clinical research. We investigate the cellular, molecular, and metabolic crosstalk underlying immune dysregulation in acute (e.g., ALF) and chronic (e.g., cirrhosis, ACLF, MASLD) liver injury. To explore this, we study both human tissue samples and in vivo models of liver inflammation using a range of advanced technological tools (e.g., liver intravital imaging, tissue multiplex staining, scRNA-seq, metabolomics). Our research aims to improve our immunological understanding of liver disease pathogenesis and identify targets for developing new immune-modulatory therapeutic approaches.

Human liver tissue multiplex staining

Current research:

- Immunomodulatory therapeutic approaches in liver disease

- Checkpoint pathways [e.g., PD-(L)1, TIGIT axis] and immune dysregulation during - acute and chronic liver injury

- Immune cell crosstalk in checkpoint inhibitor-related hepatitis

- Dysregulated immunometabolism in liver failure syndromes

- TAM (Tyro3, Axl, MerTK) receptors and myeloid cell biology in chronic liver disease

- Gut microbiota and immune landscape in non-alcoholic fatty liver disease


UKRI Medical Research Council, Rosetrees Trust, Imperial College London, NIHR Imperial Biomedical Research Centre

Selected Publications

Journal Articles

Artru F, McPhail MJW, Triantafyllou E, et al., 2022, Lipids in liver failure syndromes: a focus on eicosanoids, specialized pro-resolvinglipid mediators and lysophospholipids., Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-21

Singanayagam A, Triantafyllou E, 2021, Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting, Frontiers in Immunology, Vol:12

Triantafyllou E, Gudd CLC, Mawhin M-A, et al., 2021, PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury, Journal of Clinical Investigation, Vol:131, ISSN:0021-9738

Triantafyllou E, Woollard K, McPhail M, et al., 2018, The role of monocytes and macrophages in acute and acute-on-chronic liver failure, Frontiers in Immunology, Vol:9, ISSN:1664-3224

Triantafyllou E, Pop O, Possamai L, et al., 2017, MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure, Gut, Vol:67, ISSN:1468-3288, Pages:333-347

More Publications